Accueil・Liste d'Actions・PTC Therapeutics Inc

PTC Therapeutics Inc

Fermé

SecteurSoins de santé

72.11 -2.53

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

71.34

Max

74.18

Chiffres clés
By Trading Economics
Revenu	86M 83M
Ventes	88M 361M
P/E Moyenne du Secteur	7.597 57.002
BPA	0.92
Marge bénéficiaire	23.16
Employés	991
EBITDA	198M 162M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+33.84% upside

Dividendes
By Acuity
Prochains Résultats	3 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-59M 6.2B
Ouverture précédente	74.64
Clôture précédente	72.11

Sentiment de l'Actualité

By Acuity

26%

74%

60 / 340 Classement par Healthcare

PTC Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

12 août 2026, 23:51 UTC

Social Media

News

PTC Therapeutics acquires ST-920 gene therapy for $111 million, enhancing its rare disease portfolio. Shares are higher in after-market hours.

11 août 2026, 19:46 UTC

PTC Therapeutics Inc is trading lower amid market adjustments following last Friday's weak jobs report and ahead of upcoming U.S. inflation data releases.

10 août 2026, 19:46 UTC

PTC Therapeutics shares are higher today amid broader market uncertainty regarding the Federal Reserve's interest rate policy following last week's employment report.

7 août 2026, 21:02 UTC

PTC Therapeutics Inc shares are lower in after-market hours, reversing a trend of higher finishes over the past five sessions. No specific news was identified.

6 août 2026, 19:56 UTC

PTC Therapeutics Inc. is higher today, having reached a peak earlier in the session. No specific news was identified to explain the price action.

5 août 2026, 19:26 UTC

News

PTC Therapeutics Inc. will participate in upcoming investor conferences. Shares are lower today, remaining near the lower end of their one-month range.

4 août 2026, 20:07 UTC

PTC Therapeutics shares are higher today, buoyed by positive market sentiment amid a significant decline in crude oil prices.

3 août 2026, 19:46 UTC

News

PTC Therapeutics reported second-quarter revenue of $360.52 million and raised its full-year outlook to $1.18 billion to $1.28 billion, with shares advancing today.

31 juil. 2026, 21:01 UTC

PTC Therapeutics Inc shares rose in after-market trading, despite broader market concerns over inflation and interest rates amid rising crude oil prices.

30 juil. 2026, 22:31 UTC

News

PTC Therapeutics raised its 2026 revenue guidance after reporting strong Q2 results, with EPS of $0.92 exceeding estimates. Shares are higher in after-market trading.

29 juil. 2026, 18:26 UTC

PTC Therapeutics Inc shares are lower today, reflecting a broader decline. Market participants await the Federal Reserve's interest rate decision this afternoon.

28 juil. 2026, 18:31 UTC

News

PTC Therapeutics shares are lower as analysts anticipate a 5.6% revenue decline in Q2, contrasting with last year's growth of 24.2%.

27 juil. 2026, 20:06 UTC

PTC Therapeutics Inc shares are lower today amid broader market declines, influenced by falling oil prices and Treasury yields ahead of the Federal Reserve meeting.

22 juil. 2026, 17:16 UTC

PTC Therapeutics shares are lower today, trading near the lower end of their one-month range amid rising crude oil prices affecting the broader market.

21 juil. 2026, 18:01 UTC

PTC Therapeutics shares are higher today, reflecting positive market sentiment. The stock remains near the lower end of its one-month range.

20 juil. 2026, 19:56 UTC

News

PTC Therapeutics shares are lower as Wells Fargo cuts price target to $93.00 from $95.00 while keeping an Overweight rating.

Comparaison

Variation de prix

PTC Therapeutics Inc prévision

Objectif de Prix

By TipRanks

33.84% hausse

Prévisions sur 12 Mois

Moyen 98.64 USD 33.84%

Haut 130 USD

Bas 70 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

11 ratings

Achat

Maintien

Vente

Basé sur 11 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

60 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.